New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Now the Vice President of Research at the Lupus Foundation of America, Dr. Buie’s work stems from that curiosity as well as ...

The Novartis research study is testing a potential new investigational treatment that is a single infusion of rapcabtagene autoleucel (also called rap-cel) for patients with active, refractory lupus ...

A new study examined whether urinary biomarkers could predict future kidney complications in individuals with lupus nephritis ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol Hill purple at the 2026 National Lupus Advocacy Summit this April!

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. Lupus nephritis affects up to 60% ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...

The physical, emotional and financial toll of lupus can be invisible to those who don’t live with this disease. Lupus symptoms affect each person differently, and it can be difficult for those without ...